FDA Approves Risk Management Plan for ESAs

Cancer patients will learn more from their doctors about the possible risks and benefits of erythropoiesis-stimulating agents (ESAs) to manage anemia during chemotherapy under a new program just approved by the FDA. ESAs can be given to chemotherapy patients to…  Read More

FDA Releases Questions and Answers about ESA Medication Guides

The Food and Drug Administration now provides answers to questions about using erythropoiesis-stimulating agents (ESAs) and their FDA-approved Medication Guides.  The Medication Guides are now part of labeling for ESAs Aranesp® (darbepoetin alfa), Epogen® (epoetin alfa), and Procrit® (epoetin alfa).…  Read More